Radiopharmaceuticals Used in Clinical Trials
| Type | Examples |
|---|---|
| FDA-approved imaging radiopharmaceuticals* | 18F-FDG |
| 18F-florbetapir (Amyvid) | |
| 18F-florbetaben (Neuraceq) | |
| 18F-flutemetamol (Vizamyl) | |
| 18F-flortaucipir (Tauvid) | |
| 68Ga-DOTATATE (NETSPOT; Advanced Accelerator Applications) | |
| 64Cu-DOTATATE (Detectnet; Curium US LLC) | |
| 68Ga-PSMA-11 (University of California San Francisco and UCLA) | |
| 18F-DCFPyL (Pylarify; Progenics Pharmaceuticals, Inc.) | |
| 123I-ioflupane (DaTscan; GE Healthcare) | |
| 18F-fluciclovine (Axumin; Blue Earth Diagnostics) | |
| 8F-fluroestradiol (Cerianna; Zionexa US Corp.) | |
| 99mTc-sestamibi | |
| 18F-fluorodopa (Feinstein Institutes for Medical Research) | |
| 68Ga-PSMA-gozetotide (Locametz; Novartis) | |
| FDA-approved therapeutic radiopharmaceuticals | 177Lu-DOTATATE (Lutathera; Advanced Accelerator Applications) |
| 177Lu-PSMA-617 (Pluvicto; Novartis) | |
| Investigational agents for research under RDRC or IND | 11C-Pittsburgh compound B |
| 18F-fluorothymidine | |
| 18F-FEOBV | |
| Investigational imaging and therapeutic agents for commercialization | 18F-flupiridaz (imaging) |
| 225Ac-PSMA-617 (therapy) | |
| Investigational radiotracers to support therapeutic trials (e.g., receptor occupancy) | 18F-SPARQ |
| Radiolabeled drugs or drug candidates | 11C-ibrutinib |
| 11C-docetaxel | |
| 18F-lansoprazole |
↵* For diagnosis, staging, and monitoring of therapy or as biomarker or surrogate endpoint.